Zhong H, Wang J, Yang R, Luo Y, et al. Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial. Lancet Oncol 2026 Mar 10:S1470-2045(26)00049.
PMID: 41825453